Abstract:Abstract BACKGROUND Post-gadolinium MRI is considered the mainstay of radiological monitoring of treatment effects in patients with a glioblastoma. However, the radiotherapy(RT)-induced abnormality, pseudoprogression, is difficult to distinguish from real tumor growth. Perfusion MRI (pMRI), including Arterial Spin Labeling (ASL) and Dynamic Susceptibility Contrast (DSC), may help in this differentiation. Evaluation of RT effects is usually discussed during multidisciplinary team meetings (MDTM), after which a decision regarding (dis)continuation of anti-tumor treatment is made. It is currently unknown whether pMRI impacts such treatment decisions. This study evaluated how accurate pMRI and the MDTM are in distinguishing tumor progression from pseudoprogression in glioblastoma. MATERIAL AND METHODS Population and outcome: Glioblastoma patients who received postoperative RT were retrospectively included from 2015 to 2020. ASL, DSC, FLAIR and post-gadolinium 3D-T1 at 3 months post-RT were visually scored for probability of radiological tumor progression. These radiological scores, as well as the outcome of MDTM, were compared to the final outcome (i.e. tumor progression or pseudoprogression) set at 9 months after RT initiation. Statistical analysis: Diagnostic accuracy of pMRI, conventional MRI and MDTM was assessed by 2x2 tables, sensitivity and specificity (including AUC values). In case the MDTM was inconclusive, subsequent analysis was used to determine whether pMRI has additional value. A multivariable logistic regression model was constructed to assess which clinical parameters (age, surgery type, IDH mutation status, MGMT methylation status, KPS score, chemotherapy and pMRI evaluation) were associated with the outcome of the MDTM assessment. RESULTS Sixty-five patients with a glioblastoma met the inclusion criteria (40 male, mean age 60+/-13 years, median KPS of 90). For all METHODS , the sensitivity for detecting true disease progression was poor to moderate (32-62%). Although sensitivity was higher when adding pMRI to conventional imaging (56% versus 32%), specificity was lower (80% versus 93%). AUC values were comparable (range 0.63-0.74), but highest for MDTM evaluation (0.74). For the 26% of patients where MDTM was inconclusive, pMRI shows increased sensitivity compared to conventional MRI in detecting tumor progression (respectively 36% versus 0%). The multivariable regression analysis showed significant associations for KPS score (OR = 0.84 (95% CI: 0.77-0.91)) and radiological assessment based on pMRI with MDTM outcome (OR = 0.09 (95% CI: 0.02-0.52)). CONCLUSION This study shows that perfusion MRI has added value for detection of tumor progression within the MDTM assessment in clinical decision-making for glioblastomas, especially when the MDTM outcome is uncertain. For this decision, the role of perfusion MRI and the KPS score are most important.

Low rCBV values in glioblastoma tumor progression under chemoradiotherapy

Correlation between rCBV Delineation Similarity and Overall Survival in a Prospective Cohort of High-Grade Gliomas Patients: The Hidden Value of Multimodal MRI?

Analysis of the Mismatched Manifestation Between Rcbf and Rcbv Maps in Cerebral Astrocytomas.

Identification of a Single-Dose, Low-Flip-Angle-Based CBV Threshold for Fractional Tumor Burden Mapping in Recurrent Glioblastoma

Reproducibility of rCBV in glioblastomas using T2*-weighted perfusion MRI: an evaluation of sampling, normalization, and experience

Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma

Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab

Diagnosing Progression in Glioblastoma—Tackling a Neuro-Oncology Problem Using Artificial-Intelligence-Derived Volumetric Change over Time on Magnetic Resonance Imaging to Examine Progression-Free Survival in Glioblastoma

Radiomics analysis of cerebral blood flow suggests a possible link between perfusion homogeneity and poor glioblastoma multiforme prognosis

The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma

P11.07.A PERFUSION-MRI BASED DIFFERENTIATION BETWEEN EARLY TUMOR PROGRESSION AND PSEUDOPROGRESSION IN GLIOBLASTOMA AND ITS USE IN CLINICAL PRACTICE

Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma

ASL, DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating glioma recurrence from post-treatment changes

Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI

Advanced Multimodal Imaging in Differentiating Glioma Recurrence from Post-Radiotherapy Changes.

Evaluation of Perfusion MRI Value for Tumor Progression Assessment after Glioma Radiotherapy

Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures

New Subependymal Enhancement After Radiation Therapy in High-Grade Glioma: Utilizing Morphological Features and DSC Perfusion MRI in Differentiate Progression and Post-Radiation Changes

Implementation and evaluation of a dynamic contrast enhanced mr perfusion protocol for glioblastoma using a 0.35T mri-Linac system

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results.